<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami, Yulong Chen, Swetha Anandhan, Péter M. Szabó, Sreyashi Basu, Jorge Blando, Wenbin Liu, Jan Zhang, Seanu Meena Natarajan, Liangwen Xiong, Baoxiang Guan, Shalini S. Yadav, Abdel Saci, James P. Allison, Matthew D. Galsky, Padmanee Sharma
Abstract
mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.
Topics & Concepts
ARID1AMutationImmune checkpointCancer researchMedicineImmune systemImmunologyImmunotherapyOncologyBiologyGeneticsGeneCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsPeptidase Inhibition and Analysis